The paradox of early antibiotic treatment in vulnerable preterm infants—intended to prevent infection yet potentially increasing sepsis risk—may finally have a mechanistic explanation with profound implications for neonatal care protocols. This discovery could reshape how clinicians balance infection prevention against microbiome disruption in the most fragile patients.
Analysis of nearly 5,000 fecal samples from preterm infants across three continents revealed that antibiotic exposure delays normal gut microbiome maturation, with this developmental lag accounting for over one-third of late-onset sepsis risk. The critical missing element appears to be DL-endopeptidase, a bacterial enzyme that processes peptidoglycan fragments into muramyl dipeptide. When this enzyme is deficient, the immune system's NOD2 receptors remain underactivated, leading to impaired macrophage function and inadequate inflammatory regulation through the CYLD pathway.
This represents a significant advance beyond previous observations that antibiotics disrupt infant gut microbiomes. The identification of DL-endopeptidase as both biomarker and therapeutic target opens new intervention possibilities. Supplementation with enzyme-producing bacteria like Limosilactobacillus reuteri showed protective effects in mouse models and enhanced immune signaling in a small human trial. However, the research remains early-stage, conducted primarily in animal models with limited human validation. The complexity of preterm infant care means any probiotic intervention requires extensive safety testing before clinical implementation. Still, this work provides the first clear molecular pathway connecting antibiotic-induced dysbiosis to infection vulnerability, potentially enabling more precise risk assessment and targeted interventions for the most at-risk infants.